Biotechnology & Drugs news, Biotechnology & Drugs industry, industry News

▮ More

Rhythm Pharma Prices Public Offering Of 8.11 Mln Shares At $18.50/Shr

ProQR Prices Public Offering Of 9.09 Mln Ordinary Shares At $5.50/Shr

Sun Pharma Launches Drizalma Sprinkle In The U.S.

Today's Top 5 Losers In Healthcare Sector (KOOL, TRVI, OPGN…)

5 Top Gainers In Healthcare Sector (RETA, ABEO, CNST...)

Gilead Sciences Names Andrew Dickinson CFO - Quick Facts

Gilead Sciences Names Andrew Dickinson CFO

Johnson & Johnson Q3 adjusted earnings Beat Estimates

Healthcare Stocks That Plunged To New Lows (KLDO, COCP, ASRT...)

Unitedhealth Group, Inc. Q3 adjusted earnings Beat Estimates

Melinta Therapeutics Nearing D-Day...

RETA Surges On Trial Data, RVNC On Track, All Eyes On RLMD Today

5 Top Gainers In Healthcare Sector (ONCT, DMAC, INMD…)

Reata Shares Jump 35% After Neuromuscular Disorder Drug Study Meets Endpoint

Allergan Shareholders Oks Acquisition By AbbVie

Abbott: Omada To Provide FreeStyle Libre As Exclusive CGM - Quick Facts

FDA Approves Reyvow Tablets To Treat Migraine

Interstitial Cystitis Drug Linked To Retinal Damage: Study

An Up-Close Look At Biofrontera...

ImaginAb, AstraZeneca, Pfizer, Takeda Join To Develop CD8 ImmunoPET Technology

Genentech's Late-stage Study On Pemphigus Vulgaris Meets Primary Endpoint

Sun Pharma Launches CEQUA In US To Treat Dry Eye Disease

Genentech Says Phase III PEMPHIX Study Of Rituxan Meets Primary Endpoint

Sun Pharma Launches CEQUA For Treatment Of Dry Eye Disease In The U.S.

Biotech IPO For The Week Ahead

Industries >>

Biotechnology & Drugs News

Rhythm Pharma Prices Public Offering Of 8.11 Mln Shares At $18.50/Shr

ProQR Prices Public Offering Of 9.09 Mln Ordinary Shares At $5.50/Shr

Sun Pharma Launches Drizalma Sprinkle In The U.S.

Gilead Sciences Names Andrew Dickinson CFO

Genentech Says Phase III PEMPHIX Study Of Rituxan Meets Primary Endpoint

Sun Pharma Launches CEQUA For Treatment Of Dry Eye Disease In The U.S.